Avenue Therapeutics, Inc.
ATXIOTCHealthcare● Active
$0.31
$-0.04(-12.06%)
Market Cap$1021440
P/E Ratio—
52W High$0.9699
52W Low$0.15
Avenue Therapeutics, Inc. (ATXI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ATXI · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.21
Est. -$56.25 · +99.6%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
ATXI reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$56.25 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 8, 2026 | -$56.25 | -$0.21 | +99.6% | — | — | — |
| ▲ Q1 FY2026 | Mar 30, 2026 | -$0.57 | -$0.22 | +61.4% | — | — | — |
| — Q4 FY2025 | Nov 13, 2025 | — | -$0.21 | — | — | — | — |
| — Q3 FY2025 | Aug 14, 2025 | — | $0.11 | — | $0.00B | — | — |
| — Q2 FY2025 | May 15, 2025 | — | -$0.62 | — | — | — | — |
| — Q1 FY2025 | Mar 31, 2025 | — | $1.48 | — | — | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.94 | -$1.92 | -104.3% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$56.25
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
-$0.21
EPS Est.
-$56.25
EPS Surpr.
+99.6%
Revenue
—
Q1 FY2026
Mar 30, 2026Beat
EPS Actual
-$0.22
EPS Est.
-$0.57
EPS Surpr.
+61.4%
Revenue
—
Q4 FY2025
Nov 13, 2025
EPS Actual
-$0.21
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 14, 2025
EPS Actual
$0.11
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
May 15, 2025
EPS Actual
-$0.62
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 31, 2025
EPS Actual
$1.48
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$1.92
EPS Est.
-$0.94
EPS Surpr.
-104.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $-0.57 | $-0.57 | $-0.57 | 1 |
| Q4 FY2029 | $-0.94 | $-0.94 | $-0.94 | 1 |
| Q3 FY2029 | $-1.05 | $-1.05 | $-1.05 | 1 |
| Q2 FY2029 | $-9.00 | $-9.00 | $-9.00 | 1 |
| Q1 FY2029 | $-7.50 | $-7.50 | $-7.50 | 1 |
| Q4 FY2028 | $-19.50 | $-19.50 | $-19.50 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +99.6% | $0.55 | $0.53 | -3.67% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +61.4% | $0.29 | $0.29 | +0.00% |
| — Q4 FY2025 | Nov 13, 2025 | — | $0.75 | $0.76 | +1.20% |
| — Q3 FY2025 | Aug 14, 2025 | — | $0.50 | $0.52 | +4.00% |
| — Q2 FY2025 | May 15, 2025 | — | $0.24 | $0.25 | +4.17% |
| — Q1 FY2025 | Mar 31, 2025 | — | $0.31 | $0.30 | -3.53% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -104.3% | $1.95 | $1.88 | -3.59% |
| ▼ Q3 FY2024 | Aug 9, 2024 | -512.4% | $2.34 | $2.47 | +5.56% |
Q2 FY2026-3.67%
Report Date
May 8, 2026
EPS Beat/Miss
+99.6%
Price Before
$0.55
Price After
$0.53
Q1 FY2026+0.00%
Report Date
Mar 30, 2026
EPS Beat/Miss
+61.4%
Price Before
$0.29
Price After
$0.29
Q4 FY2025+1.20%
Report Date
Nov 13, 2025
EPS Beat/Miss
—
Price Before
$0.75
Price After
$0.76
Q3 FY2025+4.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
—
Price Before
$0.50
Price After
$0.52
Q2 FY2025+4.17%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$0.24
Price After
$0.25
Q1 FY2025-3.53%
Report Date
Mar 31, 2025
EPS Beat/Miss
—
Price Before
$0.31
Price After
$0.30
Q4 FY2024-3.59%
Report Date
Nov 14, 2024
EPS Beat/Miss
-104.3%
Price Before
$1.95
Price After
$1.88
Q3 FY2024+5.56%
Report Date
Aug 9, 2024
EPS Beat/Miss
-512.4%
Price Before
$2.34
Price After
$2.47
Avg Beat Reaction-1.83%
Avg Miss Reaction+0.98%
Beat Rate2 / 8 quarters
Largest Move+5.56% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ATXI ends December
Avenue Therapeutics, Inc. (ATXI) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.21 — beating the analyst consensus of $-56.25 by +99.6%. ATXI has beaten EPS estimates for 2 consecutive quarters. The next ATXI earnings date is expected around September 1, 2026.
Each quarter, investors track ATXI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ATXI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ATXI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ATXI earnings · 5 questionsAvenue Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ATXI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ATXI historically reports after market close (AMC).
ATXI earnings datewhen is ATXI earningsATXI next earnings datewhen does ATXI report earningsATXI earnings calendar
▸ Source: FMP · Avenue Therapeutics, Inc. SEC filings · US GAAP · Avenue Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026